Study of SIM0278 for moderate to severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests an experimental drug called SIM0278 for people with moderate to severe atopic dermatitis (eczema). It aims to see if the drug can reduce skin symptoms and is safe to use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with atopic dermatitis (eczema) by a doctor.
- You need to use moisturizer on affected skin at least twice a day for 7 days before starting the study.
- If you are able to become pregnant or get someone pregnant, you must use birth control during the study and for 90 days after the last dose.
- You cannot have used certain biologic drugs (like guselkumab, secukinumab, or omalizumab) within the last 3 months.
- You cannot have used prescription eczema creams (like steroids or JAK inhibitors) within the last 2 weeks.
- You cannot have used strong systemic medications (like cyclosporine or methotrexate) within the last 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
This trial tests a new injectable drug called SKB575 for people with moderate to severe atopic dermatitis (eczema). It aims to see how safe and effective the drug is, especially for those who haven't had success with strong creams or pills.
This study tests a new medication called IBI3033 for people with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with skin creams alone. The goal is to see if this drug can safely reduce itching, inflammation, and affected skin area.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.